IMAC Regeneration Centers Analysis Shows 81% of Patients Report Improvement in Functional Outcomes from Treatment of Musculos...
17 June 2020 - 10:00PM
IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative
medical advancements and care specializing in regenerative
rehabilitation orthopedic treatments without the use of surgery or
opioids, today announced results from an extensive internal
analysis of treatment outcomes for musculoskeletal conditions
performed at IMAC Regeneration Centers, which showed approximately
81% of IMAC patients reported improvement in movement.
IMAC analyzed functional disabilities primarily
affecting the knees, lower back, neck, shoulders, hips, legs and
ankles. Data was collected from patients during initial
examinations, re-examinations and at discharge intervals in
patients’ care plans. IMAC examined patient functional improvement
following treatment at IMAC Regeneration Centers between 2017 and
2019 utilizing standardized disability indexes for the categories
listed above.
A total of 828 patients were evaluated with each
patient receiving non-opioid medical treatments in combination with
physical therapy. More than 81%, or 678, exhibited improvement in
functionality from 1% to 79%. Eight patients regressed at least 1%,
and 142 patients showed no change in functional ability. The
average starting disability score among all patients evaluated was
64.68%, and the average disability score following treatment was
38.34%, for an average improvement in functional ability of
40.7%.
“We have long believed that the results of our
proprietary, non-opioid, non-surgical regenerative rehabilitation
therapies for movement restrictions and physical injuries compete
favorably with the current standard of care using opioids or
surgical intervention, especially as a more affordable and
conservative care option,” stated Jeff Ervin, Chief Executive
Officer of IMAC.
In IMAC’s analysis, the percentage of patients
reporting improvement for each disability category was as follows:
81% of those treated for knee conditions, 81% of those treated for
lower back conditions, 92% of those treated for neck conditions,
72% of those treated for shoulder conditions, 78% treated for hip
conditions, 86% treated for leg conditions and 80% of those with
ankle conditions. Patients included in IMAC’s analysis had a
minimum of 20% functional disability for each condition evaluated.
The average treatment duration was 80.25 days, and the average
patient age was 72.4 years.
Matt Wallis, Chief Operating Officer of IMAC
added, “Our success as providers is measured by the number of
patients who demonstrate increased movement, greater stability and
reduced pain. Our analysis reinforces that our techniques are
successful for a significant majority of our patients.”
About IMAC Holdings, Inc. IMAC
Holdings was created in March 2015 to expand on the footprint of
the original IMAC Regeneration Center, which opened in Kentucky in
August 2000. IMAC Regeneration Centers combine life science
advancements with traditional medical care for movement restricting
diseases and conditions. IMAC owns or manages 15 outpatient clinics
that provide regenerative, orthopedic and minimally invasive
procedures and therapies. It has partnered with several active and
former professional athletes, opening six Ozzie Smith IMAC
Regeneration Centers, two David Price IMAC Regeneration Centers, as
well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC
Regeneration Center. IMAC’s outpatient medical clinics emphasize
its focus around treating sports and orthopedic injuries and
movement-restricting diseases without surgery or opioids. More
information about IMAC Holdings, Inc. is available at
www.imacregeneration.com.
# # #
Safe Harbor Statement This
press release contains forward-looking statements. These
forward-looking statements, and terms such as “anticipate,”
“expect,” “believe,” “may,” “will,” “should” or other comparable
terms, are based largely on IMAC's expectations and are subject to
a number of risks and uncertainties, certain of which are beyond
IMAC's control. Actual results could differ materially from these
forward-looking statements as a result of, among other factors,
risks and uncertainties associated with its ability to raise
additional funding, its ability to maintain and grow its business,
variability of operating results, its ability to maintain and
enhance its brand, its development and introduction of new products
and services, the successful integration of acquired companies,
technologies and assets, marketing and other business development
initiatives, competition in the industry, general government
regulation, economic conditions, dependence on key personnel, the
ability to attract, hire and retain personnel who possess the
skills and experience necessary to meet customers’ requirements,
and its ability to protect its intellectual property. IMAC
encourages you to review other factors that may affect its future
results in its registration statement and in its other filings with
the Securities and Exchange Commission. In light of these risks and
uncertainties, there can be no assurance that the forward-looking
information contained in this press release will in fact occur.
IMAC Press Contact: Laura
Fristoelfristoe@imacrc.com
Investors Bret Shapiro(516)
222-2560brets@coreir.com
Source: IMAC Holdings, Inc.
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Apr 2024 to May 2024
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From May 2023 to May 2024